Compare drug alternatives
Glyxambi® Alternatives
Glyxambi®(Empagliflozin And Linagliptin) | Steglujan®(Ertugliflozin And Sitagliptin) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Oral . Learn more. | |
Dosing | |
Recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning, with or without food. Increase dose to 15 mg ertugliflozin/100 mg sitagliptin once daily in those tolerating STEGLUJAN for additional glycemic control. . Learn more. | |
Latin Shorthand | |
5 mg ertugliflozin/100 mg sitagliptin qd in AM, with or without food. Increase to 15 mg ertugliflozin/100 mg sitagliptin qd for those tolerating STEGLUJAN and needing additional glycemic control.. Learn more. | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | |
Annual Cap | |
$583 per fill . Learn more. | |
Assistance Expiration | |
12 uses. Learn more. | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions (5% or greater incidence) were urinary tract
infections, nasopharyngitis, and upper respiratory tract infections.. Learn more. | Most common adverse reactions associated with ertugliflozin
(incidence ≥5%): female genital mycotic infections.
Most common adverse reactions associated with sitagliptin
(incidence ≥5%): upper respiratory tract infection, nasopharyngitis
and headache. In the add-on to sulfonylurea and add-on to insulin
studies, hypoglycemia was also more commonly reported in patients
treated with sitagliptin compared to placebo.. Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | |
Special Populations | |